Immune peptides: adaptive vs innate

LL-37 vs Thymosin Alpha-1

Comparing LL-37 and Thymosin Alpha-1 across evidence, dosing, mechanisms, and research areas.

Compound A

vs

Compound B

Thymosin Alpha-1—

Category

immune

immune

Molecular weight

—

3108.29 g/mol

Half-life

—

~2 hours

Admin routes

—

subcutaneous

Research areas

—

Immune modulationChronic infections (Hep B/C)Cancer immunotherapy adjunctVaccine response enhancementSepsis/critical care

Typical dosing

—

1500–3000 mcg · 2-3x weekly · 4-12 weeks

FDA status

research-only

Not FDA-approved in US. Approved in 37+ countries as Zadaxin (thymalfasin)

WADA status

—

Not listed

PubMed studies

—

857

Full profile →Full profile →

More Comparisons

bpc-157 vs tb-500 cjc-1295 vs ipamorelin semaglutide vs tirzepatide ghk-cu vs ghk ghrp-2 vs ghrp-6 igf-1-lr3 vs igf-1-des semax vs selank epithalon vs ghk-cu bpc-157 vs ghk-cu pt-141 vs kisspeptin semaglutide vs aod-9604 tirzepatide vs mk-677 bpc-157 vs cerebrolysin tesamorelin vs cjc-1295 mk-677 vs ipamorelin mots-c vs nad-plus cerebrolysin vs semax epithalon vs nad-plus semaglutide vs retatrutide